The present invention relates to compounds of Formula I as shown below, wherein the definitions of A, X, R
1
, R
3
, R
4
, R
5
, R
6
, R
7
, R
8
, and R
9
are provided in the specification. Compounds of Formula I are useful for the treatment of diseases associated with γ-secretase activity, including Alzheimer's disease.
The present invention relates to compounds of Formula I as shown below, wherein the definitions of A, R
1
R
2
, R
3
, R
4
, R
5
, R
6
, R
7
, and R
8
are provided in the specification. Compounds of Formula I are useful for the treatment of diseases associated with γ-secretase activity, including Alzheimer's disease.
The present invention relates to compounds of Formula I as shown below, wherein the definitions of A, X, Y, R
1
R
2
, R
3
, R
4
, R
5
, R
6
, R
7
, R
8
, and R
9
are provided in the specification. Compounds of Formula I are useful for the treatment of diseases associated with γ-secretase activity, including Alzheimer's disease.
The present invention relates the use of compounds having the general Formula I, wherein the definitions or R1 and R2 are provided in the specification. Said compounds of Formula I are useful for the synthesis of a variety of g-secretase modulators, which are in turn useful for the treatment of diseases associated with y-secretase activity, including Alzheimer´s disease.
The present invention relates to compounds having the general Formula (I) with the definitions of R
1
, R
2
, R
3
, and R
4
given below, and/or a salt or ester thereof.
Furthermore the invention relates to the use of said compounds for the treatment of Alzheimer's disease and their use for the modulation of γ-secretase activity.